Immunovant (IMVT) Gains as Roivant Sciences Ltd. Explores Takeover
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Investors Poured More Money Into Stocks in Past 5 Months Than Last 12 Years, Says BofA, Analysts Worried About Stretched Valuations
- Amazon.com warehouse workers vote to reject forming union in Alabama
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Immunovant (NASDAQ: IMVT) gains 50% pre-open after Roivant Sciences Ltd. discloses in an amended 13D that it has engaged Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and SVB Leerink LLC to serve as its financial advisors in connection with the evaluation of a potential transaction involving the Issuer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ginkgo Bioworks Said to Weigh Over $20B Deal with Soaring Eagle Acquisition (SRNGU) - Bloomberg
- Cellebrite to List on Nasdaq Through Merger with TWC Tech Holdings II Corp. (TWCT)
- China set to clear Tencent's $3.5 billion Sogou (SOGO) deal subject to data security conditions - Reuters (Earlier)
Create E-mail Alert Related Categories13Ds, Hot M&A, Mergers and Acquisitions, Rumors
Related EntitiesJPMorgan, Goldman Sachs, 13D, Pre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!